Please login to the form below

Not currently logged in
Email:
Password:

Generics account for 80 per cent of US prescriptions

IMS Health study finds savings of $193bn last year

Generic prescribing increased sharply in the US last year as a number of major pharma brands went off-patent.

The Generic Drug Savings In The US study, conducted for the Pharmaceutical Association (GPhA) by IMS Health, found generics now account for nearly 80 per cent of US prescriptions.

2011 saw the largest year-on-year increase in US generic prescribing since 1998, according to the study, which also found generics saved US consumers, taxpayers, federal and state governments and other payers $1.07tn between 2002 and 2011. 

The sharp rise in annual savings is linked to the introduction of generics competition for several significant brands, headed up by the former top-selling prescription medicine Pfizer's Lipitor (atorvastatin).

The period also saw generic competition hit Lilly's Zyprexa (olanzapine) and Janssen's Levaquin (levofloxacin). 

Ralph Neas, president and CEO of GPhA, said: “The Generic Drug Savings study shows conclusively that, as Congress and the White House gear up for the fiscal challenges facing them in the coming year, generic and biosimilar utilisation are the best places to go for the 'offsets' that everyone will be seeking. 

“The sustainability of the health care system and the national economy depend in significant measure on the availability of affordable medicines”

A number of generic drug manufacturers stepped up to commend the study, including Ranbaxy Pharmaceuticals.

“Thousands of generic drugs are available in the US,” said Venkat Krishnan, senior vice president and regional director of Americans, Ranbaxy, “and all are manufactured and inspected under the same strict guidelines as brand name drug.

“With every prescription filled (some 80 per cent of all prescriptions written in 2011), patients taking generics receive the same medicine, with the same quality and result, but at a much lower cost.”

Krishnan also said that the savings for consumers using traditional generics could be duplicated in the biopharmaceutical market. 

“We view biologics as the next generation of generic innovation, and Ranbaxy has been hard at work positioning itself as a player in this space,” explained Krishnan. “It is important that the FDA maintains its commitment to biosimilars and that it ensures a workable pathway for such life saving treatments in the US market.”

6th August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

A new reality for healthcare
When mobile phones came onto the mass market it would have been difficult to see how they were to develop into the ubiquitous multimedia devices they are now. Their power,...
Digital-green-grey.jpg
Are you getting these benefits from your digital technology?
Your organisation switched from ‘paper to glass’, buying the latest mobile devices and hiring digital agencies to fill them with eye-catching content. But what happened?...
Alzheimer's: the numbers we cannot forget
In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the...

Infographics